Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

Video

In Partnership With:

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable (MSS).

Bendell says that 95% of patients with metastatic CRC are not microsatellite high, and treatments for them must be developed. Preliminary results of combinations with immunotherapy have shown promising response rates.

The combination of the PD-1 inhibitor atezolizumab (Tecentriq) with the MEK inhibitor cobimetinib (Cotellic) showed impressive preliminary results, and the combination has now moved into a randomized phase III global study.

Related Videos
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD
James Knight, MD
Jason Efstathiou, MD, DPhil